Perfromance Wealth Partners LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Perfromance Wealth Partners LLC purchased 735 shares of Alnylam Pharmaceuticals, totaling approximately $240,000, as per their SEC filing.
• Analysts have a consensus rating of "Moderate Buy" for Alnylam Pharmaceuticals with a consensus target price of $457.08.
• In the latest quarterly earnings, Alnylam reported earnings per share of $0.32, significantly exceeding the expected loss of $0.54.

Perfromance Wealth Partners LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 735 shares of the biopharmaceutical company's stock, valued at approximately $240,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Envestnet Portfolio Solutions Inc. boosted its position in Alnylam Pharmaceuticals by 34.3% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 1,164 shares of the biopharmaceutical company's stock worth $380,000 after purchasing an additional 297 shares during the last quarter. Sequoia Financial Advisors LLC boosted its position in Alnylam Pharmaceuticals by 15.4% in the second quarter. Sequoia Financial Advisors LLC now owns 3,917 shares of the biopharmaceutical company's stock worth $1,277,000 after purchasing an additional 522 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Alnylam Pharmaceuticals by 15.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 312,216 shares of the biopharmaceutical company's stock worth $100,552,000 after purchasing an additional 41,292 shares during the last quarter. OFI Invest Asset Management boosted its position in Alnylam Pharmaceuticals by 26.2% in the second quarter. OFI Invest Asset Management now owns 381 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 79 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 47.3% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,390 shares of the biopharmaceutical company's stock valued at $4,368,000 after buying an additional 4,302 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ALNY shares. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a research note on Monday, August 4th. JPMorgan Chase & Co. reduced their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an "overweight" rating for the company in a research note on Monday. Evercore ISI lifted their target price on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a research note on Thursday, September 11th. Citigroup increased their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Finally, Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $457.08.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $464.95 on Tuesday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The company has a market cap of $60.95 billion, a price-to-earnings ratio of -188.24 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21. The stock's 50 day simple moving average is $452.27 and its two-hundred day simple moving average is $347.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at $397,724.38. This trade represents a 97.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director owned 775 shares of the company's stock, valued at $362,390. This trade represents a 95.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock valued at $44,160,261 over the last ninety days. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.